Megavitamin-B6 syndrome, also known as hypervitaminosis B6 or vitamin B6 toxicity, is a collection of symptoms that results from chronic supplementation or acute overdose of vitamin B6. Although vitamin B6 is water-soluble, it accumulates in muscle, plasma, liver, red blood cells and other protein-bound tissue with a half-life of roughly two to four weeks, allowing excess intake to build up. The hallmark effect is peripheral sensory neuropathy, with numbness, pins-and-needles sensations and burning in the limbs, along with unsteady gait, heightened sensitivity to stimuli and reduced vibration and position sense. The condition is generally, though not always, reversible once supplementation stops, with most cases resolving within six months, though symptoms can briefly worsen before they improve.
Facts
Classification
ICD-10 ChapterIV: Endocrine, Nutritional and Metabolic Diseases 1 Communicable or Non-communicable Transmission Route Causative Agent
Causative Agent (category) Sources
1. Wikipedia: ICD-10
WikipediaList of chapters, Chapter IVQuote, List of chapters, Chapter IV
Endocrine, nutritional and metabolic diseases
View the Source 2. World Health Organization: Noncommunicable diseases (fact sheet)
World Health OrganizationLead section, transmission-route statement (inferred from disease-category)
The main types of NCDs are cardiovascular diseases (such as heart attacks and stroke), cancers, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma) and diabetes.
Main Types section
The main types of NCDs are cardiovascular diseases (such as heart attacks and stroke), cancers, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma) and diabetes.
View the Source 3. Megavitamin-B6 syndrome (Wikipedia)
lead sentence 2Quote, lead sentence 2
While it is also known as hypervitaminosis B6, vitamin B6 toxicity and vitamin B6 excess, megavitamin-b6 syndrome is the name used in the Tenth Revision of the International Classification of Diseases, ICD-10.
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.